|
|||
|
Multiple Sclerosis Information
Favorite Links
This Month
Month Archive
|
« Previous
Saturday, July 25
by
All About MS
on Sat 25 Jul 2009 12:00 AM CST
Natalizumab is an antibody directed against integrin alpha4 that reduces disease activity in patients with multiple sclerosis (MS) by blocking migration of T and B cells into the Central Nervouse System (CNS). The goal of this study was more »
Monday, July 20
by
All About MS
on Mon 20 Jul 2009 01:00 AM CST
Thank you for your comment on my blog. I did not write that article. I reported it from Associated Press - Jun. 29, 2009. I put Associated Press - Jun. 29, 2009 on the bottom of the article to indicate that I did not write it. But more »
Thursday, July 16
by
All About MS
on Thu 16 Jul 2009 11:28 AM CST
Prednisone or acetaminophen may significantly control flulike symptoms (FLSs) in patients with relapsing multiple sclerosis (MS) who are treated with interferon (IFN) beta-1a, according to a study presented here at the more »
Wednesday, July 15
by
All About MS
on Wed 15 Jul 2009 10:28 AM CST
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the launch of the innovative individually adjustable electronic injection device RebiSmart(TM) for the self-administration of Rebif(R) (interferon beta-1a), the company's disease-modifying more »
by
All About MS
on Wed 15 Jul 2009 12:00 AM CST
Patients with multiple sclerosis (MS) who adhere to their treatment with interferon (IFN) beta-1a without interruption have lower relapse and progression rates than patients who do not adhere to their medication as regularly more »
Monday, July 13
by
All About MS
on Mon 13 Jul 2009 12:00 AM CST
company said late Friday it confirmed the presence of progressive multifocal leukoencephalopathy, or PML, on Tuesday. Biogen said the patient, who lives outside the U.S., had been using Tysabri for 30 months. Three of the ten more »
Monday, June 29
by
All About MS
on Mon 29 Jun 2009 04:55 PM CST
A new electronic, multidose, autoinjection device improves subcutaneous delivery of interferon beta (IFNB)-1a in patients with relapsing multiple sclerosis (MS), according to a study presented here at the 19th Meeting of the European more »
Monday, June 15
by
All About MS
on Mon 15 Jun 2009 09:46 AM CST
Patients with multiple sclerosis who are treated with a cumulative dose of 82 mg/m[2 of Mitoxandrone (MTX) are at a 2.7 higher risk of developing acute leukemia (AL), according to a late-breaking abstract presented on April 30 more »
Monday, May 25
by
All About MS
on Mon 25 May 2009 01:17 PM CST
Emphasis on the reduction of relapses as early as possible is important because you may not always recover your previous level of functioning after a relapse. Quite often, irreversible more »
Saturday, May 23
by
All About MS
on Sat 23 May 2009 10:19 AM CST
The risk of developing progressive multifocal leukoencephalopathy (PML), a viral brain infection, in patients with multiple sclerosis (MS) taking the drug natalizumab (Tysabri) appears to be much lower - and the infection more »
Monday, May 11
by
All About MS
on Mon 11 May 2009 08:36 AM CST
with MRI findings. The CHAMPIONS ten-year follow up showed that patients treated immediately after their first episode had significantly less chance of experiencing a second attack versus those patients with delayed treatment. These results at ten years also indicate that 80 percent more »
Saturday, May 9
by
All About MS
on Sat 09 May 2009 09:07 AM CST
New data presented today provided evidence that long-term treatment with COPAXONE® (glatiramer acetate injection) may offer sustained protection from neuronal/axonal injury. This protective effect was reflected biologically by a significant more »
Monday, April 20
by
All About MS
on Mon 20 Apr 2009 12:05 PM CST
Health Canada has approved an expanded indication for glatiramer acetate injection (Copaxone) to include the treatment of patients who have experienced a single demyelinating event, accompanied by abnormal magnetic resonance imaging (MRI) more »
Thursday, April 16
by
All About MS
on Thu 16 Apr 2009 07:00 AM CST
Researchers at Aurora St. Luke's Medical Center have developed a technique that counteracts an unusual, but serious, side effect from natalizumab (Tysabri®), a drug that more »
Friday, April 10
by
All About MS
on Fri 10 Apr 2009 03:00 AM CST
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced five-times as many multiple sclerosis (MS) patients taking TYSABRI® (natalizumab) were free from disease activity versus placebo in the overall patient population. Results more »
|
||